LivaNova PLC (LIVN) Deep Dive Video
Summary
LivaNova pairs a leadership-positioned Essenz upgrade cycle and recurring surgical consumables with double-digit neuromodulation growth, supporting a $155.88 probability-weighted five-year target despite execution and reimbursement risks.
View LIVN stock page · Read the LIVN research report
Loading the video player…